Menu

In Utero Transplant in First Clinical Trial Successful

Doctors treated the fetus, who has alpha thalassemia major, with cells from her mother’s bone marrow.

May 30, 2018
Jim Daley

(From left) Nichelle Obar, Elianna Constantino, and Tippi MacKenzie, the pediatric surgeon who performed the transplantNOAH BERGER/UCSF

Pediatric surgeons at the University of California, San Francisco, have treated a second-trimester fetus with stem cells taken from her mother’s bone marrow. The baby, born in February, was the first patient enrolled in the world’s first clinical trial using stem cells transplanted prior to birth. She is “apparently healthy,” despite living with a deadly genetic disease called alpha thalassemia, according to a statement from the university.

Tippi MacKenzie, a pediatric surgeon at the University of California, San Francisco (UCSF) Benioff Children’s Hospital, led the team that performed the transplant. “It is too early to say how effective the stem cell transplantation will be, but we are encouraged by how well she and her mother have tolerated the treatment,” she says in the statement. “Her healthy birth suggests that fetal therapy is a viable option to offer to families with this diagnosis.”

The baby, Elianna Constantino, was born on February 1 to Nichelle Obar after five blood infusions and one stem cell transplant over the course of four months in a clinical trial funded by the California Institute for Regenerative Medicine. The trial began in 2016 to investigate using stem cells to treat thalassemia. Constantino has a lethal form of it, called alpha thalassemia major, which is caused by abnormalities on the HBA1 and HBA2 genes, reduces the body’s ability to produce hemoglobin, according to the National Institutes of Health’s Genetics Home Reference, and can cause swelling of the liver or heartBabies with alpha thalassemia typically die before birth or are stillborn.

During pregnancy, a routine ultrasound performed at a medical center in Hawaii, where the family resides, detected the fetus had an enlarged heart. According to the UCSF statement, intrauterine blood transfusions were required to treat the swelling before the stem cell transplant could be performed. The transplant was given during one of the transfusions.

“Elianna’s doing great,” Obar tells The New York Times. “I’m not disappointed at all. If it works, great. If it didn’t, we’re O.K. with it. We’ll celebrate all the little accomplishments. I’m glad we did it.”

“Once universally fatal, thalassemia can now be managed as a chronic disease,” says Elliott Vichinsky, a hematologist and the founder of the Northern California Comprehensive Thalassemia Center at UCSF Benioff who is overseeing the baby’s treatment, in the statement. “In utero stem-cell transplantation may take it one step further: as a disease that can be successfully treated before birth.”

“Everybody has a perfect donor when they’re a fetus, and that’s the mom,” MacKenzie tells The New York Times. According to the article, she plans to perform a few more transplants, monitor the patients’ progress, and then decide how to proceed.

Correction (May 31)The original version of this story erroneously stated the fetus was the first to receive a stem cell transplant in utero; she is the first to have recieved such a transplant as part of a clinical trial. The article has been corrected to reflect this; The Scientist regrets the error.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!